Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda’s 1st Cell Therapy Alofisel Misses Goal in Key PIII Study
Takeda Pharmaceutical said on October 18 that its cell therapy product Alofisel (darvadstrocel) for the treatment of complex Crohn’s perianal fistulas (CPF) failed to meet its primary endpoint in a PIII study being conducted for US regulatory filing. According to…
To read the full story
Related Article
- Takeda to Halt Sales of Cell Therapy Alofisel in Japan
January 15, 2026
BUSINESS
- Asahi Kasei Starts Japan PIII of Extended Teribone Dosing
May 19, 2026
- Allergan Files Botox Vista for Forehead Wrinkles
May 19, 2026
- Stella Begins Japan PIII of BNCT for Recurrent Glioblastoma
May 19, 2026
- Enhertu Earns 2 US Approvals in HER2-Positive Early Breast Cancer
May 19, 2026
- Kissei Urges Halt to New Tavneos Use after Fatal Liver Injury Reports
May 18, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…